BioMarin Pharmaceutical Statistics
Total Valuation
BMRN has a market cap or net worth of $11.73 billion. The enterprise value is $11.40 billion.
Market Cap | 11.73B |
Enterprise Value | 11.40B |
Important Dates
The next estimated earnings date is Thursday, February 20, 2025, after market close.
Earnings Date | Feb 20, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
BMRN has 190.58 million shares outstanding. The number of shares has increased by 0.93% in one year.
Current Share Class | 190.58M |
Shares Outstanding | 190.58M |
Shares Change (YoY) | +0.93% |
Shares Change (QoQ) | -1.67% |
Owned by Insiders (%) | 0.78% |
Owned by Institutions (%) | 91.85% |
Float | 179.17M |
Valuation Ratios
The trailing PE ratio is 36.62 and the forward PE ratio is 16.61. BMRN's PEG ratio is 0.67.
PE Ratio | 36.62 |
Forward PE | 16.61 |
PS Ratio | 4.24 |
Forward PS | 3.87 |
PB Ratio | 2.17 |
P/TBV Ratio | 2.37 |
P/FCF Ratio | 36.66 |
P/OCF Ratio | 28.28 |
PEG Ratio | 0.67 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 26.75, with an EV/FCF ratio of 35.63.
EV / Earnings | 35.37 |
EV / Sales | 4.14 |
EV / EBITDA | 26.75 |
EV / EBIT | 34.92 |
EV / FCF | 35.63 |
Financial Position
The company has a current ratio of 4.27, with a Debt / Equity ratio of 0.11.
Current Ratio | 4.27 |
Quick Ratio | 2.39 |
Debt / Equity | 0.11 |
Debt / EBITDA | 1.37 |
Debt / FCF | 1.88 |
Interest Coverage | 20.16 |
Financial Efficiency
Return on equity (ROE) is 6.25% and return on invested capital (ROIC) is 3.40%.
Return on Equity (ROE) | 6.25% |
Return on Assets (ROA) | 3.00% |
Return on Capital (ROIC) | 3.40% |
Revenue Per Employee | $809,412 |
Profits Per Employee | $94,764 |
Employee Count | 3,401 |
Asset Turnover | 0.40 |
Inventory Turnover | 1.19 |
Taxes
In the past 12 months, BMRN has paid $69.16 million in taxes.
Income Tax | 69.16M |
Effective Tax Rate | 17.67% |
Stock Price Statistics
The stock price has decreased by -34.16% in the last 52 weeks. The beta is 0.29, so BMRN's price volatility has been lower than the market average.
Beta (5Y) | 0.29 |
52-Week Price Change | -34.16% |
50-Day Moving Average | 65.49 |
200-Day Moving Average | 77.13 |
Relative Strength Index (RSI) | 32.71 |
Average Volume (20 Days) | 1,517,850 |
Short Selling Information
The latest short interest is 4.54 million, so 2.38% of the outstanding shares have been sold short.
Short Interest | 4.54M |
Short Previous Month | 5.21M |
Short % of Shares Out | 2.38% |
Short % of Float | 2.54% |
Short Ratio (days to cover) | 3.06 |
Income Statement
In the last 12 months, BMRN had revenue of $2.75 billion and earned $322.29 million in profits. Earnings per share was $1.68.
Revenue | 2.75B |
Gross Profit | 1.44B |
Operating Income | 326.41M |
Pretax Income | 298.68M |
Net Income | 322.29M |
EBITDA | 426.09M |
EBIT | 326.41M |
Earnings Per Share (EPS) | $1.68 |
Balance Sheet
The company has $930.44 million in cash and $602.69 million in debt, giving a net cash position of $327.76 million or $1.72 per share.
Cash & Cash Equivalents | 930.44M |
Total Debt | 602.69M |
Net Cash | 327.76M |
Net Cash Per Share | $1.72 |
Equity (Book Value) | 5.41B |
Book Value Per Share | 28.41 |
Working Capital | 2.34B |
Cash Flow
In the last 12 months, operating cash flow was $414.70 million and capital expenditures -$94.81 million, giving a free cash flow of $319.89 million.
Operating Cash Flow | 414.70M |
Capital Expenditures | -94.81M |
Free Cash Flow | 319.89M |
FCF Per Share | $1.68 |
Margins
Gross margin is 52.35%, with operating and profit margins of 11.86% and 11.71%.
Gross Margin | 52.35% |
Operating Margin | 11.86% |
Pretax Margin | 14.22% |
Profit Margin | 11.71% |
EBITDA Margin | 15.48% |
EBIT Margin | 11.86% |
FCF Margin | 11.62% |
Dividends & Yields
BMRN does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.93% |
Shareholder Yield | -0.93% |
Earnings Yield | 2.75% |
FCF Yield | 2.73% |
Analyst Forecast
The average price target for BMRN is $94.20, which is 53.10% higher than the current price. The consensus rating is "Buy".
Price Target | $94.20 |
Price Target Difference | 53.10% |
Analyst Consensus | Buy |
Analyst Count | 21 |
Revenue Growth Forecast (5Y) | 8.94% |
EPS Growth Forecast (5Y) | 43.04% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
BMRN has an Altman Z-Score of 7.71 and a Piotroski F-Score of 6.
Altman Z-Score | 7.71 |
Piotroski F-Score | 6 |